ReviewFrontiers in aging2026
Dietary pyrroloquinoline quinone and spermidine in healthy longevity: targeting the hallmarks of aging.
Review in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aging is a multifaceted biological process driven by interconnected cellular and molecular hallmarks. As geroscience increasingly prioritizes healthspan over lifespan, nutritional interventions targeting multiple aging mechanisms have gained attention as accessible strategies to mitigate age-related functional decline. Objective: This mini review synthesizes recent evidence on how the bioactivities of two food-derived geroprotective compounds, pyrroloquinoline quinone (PQQ) and spermidine (SPD), intersect with the hallmarks of aging and their distinct and overlapping roles in maintaining cellular homeostasis. Findings: PQQ primarily functions as a mitochondrial and redox regulator, enhancing mitochondrial biogenesis and bioenergetic capacity through the AMP-activated protein kinase (AMPK) and sirtuin1 (SIRT1)/peroxisome proliferator-activated receptor gamma coactivator 1-alpha pathways. In contrast, SPD acts as a key regulator of cellular quality control by inducing macroautophagy and preserving proteostasis, largely through modulation of histone and autophagy-related protein acetylation. These complementary mechanisms converge on several key hallmarks of aging, including genomic instability, deregulated nutrient sensing, mitochondrial dysfunction, and chronic inflammation. Conclusion: The anti-aging mechanisms of PQQ and SPD originate from distinct upstream biochemical processes but converge on shared signaling hubs, including the AMPK/SIRT1 axis and autophagy-related networks. This convergence suggests a coordinated network-level complementarity that may offer a more robust intervention against age-related decline than targeting independent pathways alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.